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another 3.6 million are at an increased risk. In men over 64 years
of age, 80% of hip fractures are attributed to osteoporosis,
costing a national direct expenditure of $13.8 billion in 2000.
Earliest diagnosis is through a bone density test, which could
help in prevention of hip fractures and signiﬁcant savings in
health care costs. This study examines the various physician and
patient factors, which inﬂuence the bone density test prescribing
for osteoporosis in male ambulatory patients. METHODS:
Patient factors such as age, race, geographical location and
payment source, and Physician factors such as specialty and
referral status were used to determine their inﬂuence on the
number of bone density tests prescribed. Data from the National
Ambulatory Medical Care Survey (NAMCS) 2002 were utilized.
Male patients with principal diagnosis of osteoporosis (ICD-9-
CM code 733.00) with age more than or equal to 50 years were
analyzed using multiple linear and binomial logit regression
models. RESULTS: The number of bone density tests performed
were independent of patients’ geographic region (R2 = 0.111).
White patients were prescribed more bone density tests com-
pared to other races (R2 = 0.436). Patients above 75 years of age
and patients with Federal source of payments were prescribed
more bone density tests than other patients (R2 = 0.345).
Numbers of bone density tests were not inﬂuenced by whether
the patient was referred (R2 = 0.027). Family Practice physicians
prescribed more bone density tests compared to other specialties
(R2 = 0.326). CONCLUSIONS: The numbers of bone density
tests prescribed are signiﬁcantly inﬂuenced by patients’ race, age
and source of payments, and physician’s specialty. Bone density
screening for men over 50 years of age appears to be an optimal
approach to manage osteoporosis in men.
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OBJECTIVES: A preexisting fracture is a very strong predictor
of subsequent osteoporotic fractures, emphasizing the need to
aggressively treat patients with existing osteoporotic fractures.
The objectives of the study are to examine the prevalence of drug
treatment and factors associated with drug treatment among
elderly nursing home (NH) admissions with an indication of
osteoporotic fracture. METHODS: The Minimum Data Set for
Nursing Home Assessment and Care Screening (MDS) Version
2.0 and physicians’ medication orders from 1999 were utilized
for this study. The outcome was the use of anti-osteoporotic drug
therapy at NH admission. Independent variables included
patient demographics, comorbidities, functional capabilities
(activities of daily living or ADLs), and cognitive performance
(MDS-COGS). Multivariate analysis was conducted using logis-
tic regression with Generalized Estimating Equations (GEE) to
adjust for clustering within NH facilities. RESULTS: A total of
2673 NH residents were identiﬁed with documentation of osteo-
porotic fracture within 180 days or affecting current care at
admission; however, only 642 (24.02%) received anti-osteo-
porotic drug therapy at admission. Gender (p < 0.0001), age (p
= 0.0394), and functional capabilities (p = 0.0002) were signiﬁ-
cantly associated with the use of anti-osteoporotic drug. Non-
signiﬁcant factors were region, race, education, comorbidity and
cognition. Treatment was less likely for male residents (OR:
0.45; 95% CI, 0.33–0.62) and residents older than 85 (OR: 0.79;
95% CI, 0.67–0.97). Those who were independent in terms of
ADLs were more likely to receive drug treatment (OR: 2.54;
95% CI, 1.27–5.07), compared to those who were fully depen-
dent. CONCLUSIONS: While osteoporotic fracture is common
among the NH elderly population, the majority remained
untreated. Increasing age was inversely related to receipt of anti-
osteoporotic drugs. Female elderly and those with fewer limita-
tions in daily activities were more likely to receive drug therapy
for osteoporosis.
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OBJECTIVE: To evaluate the impact of an osteoporosis therapy
intervention program in a health plan setting. METHODS: A
clinical team of pharmacists, obstetricians/gynecologists and
endocrinologists designed and implemented an educational ini-
tiative for physicians and members. Medical and pharmacy
claims data for female enrollees over the age of 40 were retrieved
for the time period of July, 2002 through June, 2003. Criteria
for targeted patients included a fracture history (deﬁned by ICD-
9 and CPT codes) and negative history of estrogen/progestin use
over the 1-year period, and four-month negative history of osteo-
porosis therapy (alendronate, risedronate, calcitonin, raloxifene,
or teriparatide). Physicians received a patient list, an educational
tool for management of osteoporosis and coupons for a free ﬁrst-
month supply of a bisphosphonate. Targeted members received
a 17-page handbook highlighting drug treatment, lifestyle mod-
iﬁcations, and information regarding prescription drug discount
programs. The impact of the intervention was analyzed using
pharmacy claims data for eligible patients with pharmacy bene-
ﬁts. Primary outcome measure was deﬁned as the percent of
patients with a claim for an osteoporosis agent at three, six, and
nine-months post-intervention. Additionally, a member survey
was conducted six-months post-intervention to evaluate the
member mailing. RESULTS: There were 1612 program partici-
pants. At three, six and nine-months respectively, 3.76%
(32/852), 5.12% (40/781) and 5.97% (42/704) of eligible
patients had a claim for an osteoporosis agent. A 23% survey
response rate was achieved (364/1612). Survey results indicated
18% of responders were taking prescription osteoporosis med-
ications at that time. Post-intervention, 19% of the responders
made a doctor appointment, 15% attended the appointment,
17% received a prescription, 13% received medication samples,
and 11% ﬁlled the prescription. CONCLUSION: Survey results
indicate higher rate of medication use compared to claims data-
base analysis, which does not capture medication sampling.
Another mailing has been done to continue to improve osteo-
porosis care.
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OBJECTIVE: Several features of bisphosphonate therapy for
osteoporosis may inﬂuence patient satisfaction, including dosing
convenience. The objective of this study was to evaluate the psy-
chometric characteristics of the Osteoporosis Patient Satisfaction
Questionnaire (OPSAT-Q), which assesses patient satisfaction
with osteoporosis treatment. METHODS: Patient focus groups
and cognitive debrieﬁngs informed the development of the 16-
item OPSAT-Q, which contains four subscales: Convenience,
Conﬁdence with Daily Activities, Side Effects and Overall Satis-
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faction. Both subscale scores and a composite score (CSS) can 
be calculated, with higher scores indicating greater satisfaction.
The OPSAT-Q, Osteoporosis Targeted Quality of Life (OptQoL),
three single-item global measures related to satisfaction, and
demographic questionnaires were self-administered to eligible
women recruited from four US clinics. Participants were diag-
nosed with osteoporosis or osteopenia and currently taking daily
or weekly bisphosphonate treatment. Reproducibility was
assessed via a follow-up questionnaire completed by participants
two-weeks post baseline. Analyses included item and scale per-
formance, internal consistency reliability, reproducibility, and
construct validity. RESULTS: A total of 104 women with a mean
age of 65 years participated. The majority was white (64.4%),
living with someone (74%), and not currently employed
(58.7%). On a scale of 0–100, individual patient subscale scores
ranged from 17 to 100 and CSS scores ranged from 44–100. All
scores showed acceptable internal consistency reliability (Cron-
bach’s a > 0.70) (range 0.72 to 0.89). Reproducibility exceeded
0.70 for all scores except Conﬁdence with Daily Activity (0.62)
and Overall Satisfaction (0.64). Signiﬁcant correlations were
found between the OPSAT-Q subscales and conceptually similar
global measures (p < 0.001). CONCLUSIONS: The ﬁndings
from this study provide evidence of the validity and reliability of
the OPSAT-Q and support the proposed composition of four
subscales and a composite score. They also support the use of
the OPSAT-Q to examine the impact of potentially more conve-
nient bisphosphonate dosing on patient satisfaction.
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OBJECTIVE: Is it safe to treat patients with opioids for chronic
non-malignant pain who have histories of substance abuse or
addicition? Mortality rates for substance abusers are three times
the general population rate. There are few outcome studies in
the medical literature. The Opioid Renewal Clinic follows
patients closely with drug testing, laboratory monitoring, and
provides group education with outside speakers. On site drug
counseling is provided to those determined to be in need. A 
full range of consultation services are available. The disciplines
that make up the clinc include Pharmacy, Nursing, Social 
Work, Internal and Addiction Medicine. Disease management
guidelines are incorporated into the structure of the clinic.
METHODS: This was a retrospective age adjusted mortality
study of 250 Primary Care consults over a two-year period to a
multidisciplinary Opioid Renewal Clinic. The most common
reason for consultation was the difﬁcult to manage patient sec-
ondary to substance abuse. The renewal clinic maintains between
80 to 100 patients. Kaplan-Meier survival curves were per-
formed for pain patients on opioids in Primary Care and the
opioid renewal clinic. Key variables were evaluated by regression
analysis. RESULTS: There were six deaths in patients in Primary
Care and two deaths in patients followed in the Renewal Clinic.
The odds ratio of deaths in usual care to clinic is three, or three
times the rate of the Renewal Clinic. Patients were between
40–60 years of age. Deaths due to known cancer, cardiac or liver
disease were excluded. Cancer deaths were predominantly lung,
and assosciated with tobacco use. CONCLUSIONS: A Multi-
disciplinary Opioid Renewal Clinic can reduce short term mor-
tatlity in high risk patients. Further studies are recommended 
to assess long term mortality rates and secondary outcomes 
on cancer prevention, disease management, and control of
depression.
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OBJECTIVES: Pain management centers provide the most
appropriate care for pure neuropathic pain. But before consult-
ing such a center, patients often indulge in “medical nomadism”,
thereby incurring substantial additional costs. This study aimed
to describe the medical trajectory and to estimate the direct costs
of a patient sample with pure neuropathic pain (i.e. with no noci-
ceptive component) during the year before their ﬁrst consulta-
tion in a pain management center. METHODS: Retrospective
data collected by patient questionnaires were used for this cross-
sectional study, in which ten pain management centers partici-
pated between January and April, 2004. A total of 116 patients
who gave written consent and were able to answer the ques-
tionnaire were assessed. The economic outcomes were the total
and refunded Direct Medical Consumption (DMC), including 
all costs directly related to the pathology: medical and para-
medical consultations, drugs, other treatments (surgery, nerve
stimulation, etc.), examinations, and hospitalizations. Costs
were determined by medical fees, ofﬁcial drugs and examinations
tariffs, and Diagnosis Related Groups (DRGs). A bootstrap 
technique was used to improve statistical strength. RESULTS:
The total and refunded average cost per patient ranges from
4650 € to 6830 € and from 3500 to 5690 €, depending on 
the hospitalization sector, private or public. The most costly
items are “Hospitalizations” and “other treatments”, represent-
ing 31% and 24% respectively of the total cost in the private 
sector, and 46% and 23% in the public sector. The “drugs” item
only represents 12% in the private and 8% in the public 
sector. CONCLUSION: This study, based mainly on recalled
declarative data, may be subjectively biased. Nonetheless, the
results give a plausible estimation of direct annual costs of 
neuropathic pain management in France before its appropriate
management in a specialized center, a ﬁeld where few data are
available.
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OBJECTIVES: To characterize hospital IV PCA pump and anal-
gesia acquisition, inventory, and logistics for acute postoperative
pain management. METHODS: Data were collected via inter-
views with 13 geographically diverse US hospitals during an
ongoing prospective, multi-center, observational study of IV PCA
for acute postoperative pain management among subjects under-
going total knee or hip replacement or abdominal hysterectomy.
An interim analysis was performed on data from 13 of 32
planned hospitals. RESULTS: Average IV PCA pump inventory
